Since February 27, the stock of pharmaceutical firm surged 20% from Rs 1,550 on February 26, 2015 after the company said there were no serious observations raised by the US drug regulator at its manufacturing facility at Waluj, Aurangabad.
The company’s chairman, Dr. Habil Khorakiwala, on a specific query by a news channel appraised the latest position in the US FDA (Food and Drug Administration) issue and informed about inspection carried out by US FDA at the company’s manufacturing facility at Waluj, Aurangabad.
“There were no serious observations raised by the said US FDA which would have bearing on the performance/operations of the Company. Hence at present we do not have any important information / announcement to be shared,” Wockhardt said in a regulatory filing.
The company made statement on a clarification on media reports titled "US FDA raises concern over Wockhardt's plant”.
Meanwhile, since February 4, the stock surged 58% after posted 14% year on year growth in its consolidated net profit at Rs 347 crore for the quarter ended December 2014. The company had profit of Rs 304 crore in a year ago quarter and Rs 3.63 crore in September 2014 quarter.
In past three months, the stock zoomed 110% from Rs 889 on December 17, 2014 compared with 7% rise in S&P BSE Sensex and 18% jump in S&P BSE Healthcare sector index.
Today, the stock opened at Rs 1,792 and touched a low of Rs 1,870 on BSE. A combined 1.34 million shares changed hands on the counter so far on BSE and NSE.
At 1234 hours, Wockhardt was up 3.4% at Rs 1,851 on BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)